https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Clin. Cancer Res. 2004 May;10(9):2944-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Clin. Cancer Res. 2004 May;10(9):2944-532004-05-01 00:00:002019-02-15 08:53:29Dendritic cell vaccination in medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Klin Padiatr 2004 May-Jun;216(3):176-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Klin Padiatr 2004 May-Jun;216(3):176-822004-05-01 00:00:002019-02-15 09:12:31Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-15 / Clin. Cancer Res. 2004 Apr;10(8):2645-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-15 / Clin. Cancer Res. 2004 Apr;10(8):2645-512004-04-15 00:00:002019-02-15 08:39:06Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-302004-04-07 00:00:002019-02-15 08:50:36Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Expert Rev Vaccines 2004 Apr;3(2):163-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Expert Rev Vaccines 2004 Apr;3(2):163-702004-04-01 00:00:002004-04-01 00:00:00The role of idiotype vaccines in the treatment of human B-cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Pneumologie 2004 Apr;58(4):210-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Pneumologie 2004 Apr;58(4):210-62004-04-01 00:00:002004-04-01 00:00:00[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Int. J. Clin. Oncol. 2004 Apr;9(2):85-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Int. J. Clin. Oncol. 2004 Apr;9(2):85-912004-04-01 00:00:002004-04-01 00:00:00Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-342004-03-01 00:00:002020-06-23 09:42:15Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / J. Exp. Clin. Cancer Res. 2004 Mar;23(1):9-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / J. Exp. Clin. Cancer Res. 2004 Mar;23(1):9-132004-03-01 00:00:002019-02-15 08:51:05Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / Cancer Sci. 2004 Mar;95(3):248-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / Cancer Sci. 2004 Mar;95(3):248-532004-03-01 00:00:002019-02-15 08:48:24Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity
